Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


UCL and Photobiotics announce partnership to tackle gastric cancer

18 October 2013

UCL, Photobiotics pursue new approach to gastric cancer
A new collaboration between University College London (UCL) and PhotoBiotics, a targeted oncology company spun out from Imperial College London in the UK, is looking to develop a multifunctional agent for use in both the diagnosis and treatment of gastric cancer.
Read: PharmaTimes